Previous Article | Next Article 
Journal of Clinical Microbiology, September 1998, p. 2745-2747, Vol. 36, No. 9
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Modification of Results of Drug Susceptibility
Tests by Coexistence of Mycobacterium avium Complex with
Mycobacterium tuberculosis in a Sputum Sample: Case
Report and Experimental Considerations
Katsuhiro
Suzuki,*
Terumi
Kimoto,
Kazunari
Tsuyuguchi,
Hisako
Matsumoto,
Akio
Niimi,
Eisaku
Tanaka,
Takako
Murayama, and
Ryoichi
Amitani
Department of Infection and Inflammation,
Chest Disease Research Institute, Kyoto University, Sakyo-ku,
Kyoto, 606 Japan
Received 23 February 1998/Returned for modification 1 May
1998/Accepted 1 June 1998
 |
ABSTRACT |
We report on a patient whose sputum contained both
Mycobacterium tuberculosis and Mycobacterium
avium complex (MAC). The MAC failed to be detected by the
PCR-based AMPLICOR test. The unrecognized coexistence of MAC in the
sample modified the results of drug susceptibility tests. Experiments
revealed that the presence of both M. tuberculosis and MAC
was not detected by the AMPLICOR test under certain conditions.
 |
TEXT |
Two direct-amplification tests, the
Gen-Probe (San Diego, Calif.) Mycobacterium tuberculosis
Direct Test (MTD) and the PCR-based AMPLICOR MYCOBACTERIUM (Roche,
Basel, Switzerland) tests, have been approved in the United
States for direct detection of tubercle bacilli in respiratory
samples that are smear positive for acid-fast bacilli (AFB)
(3). The two tests have been widely used in Japan as well
since 1995 (1, 9). We have routinely performed the rapid
detection of Mycobacterium tuberculosis and
Mycobacterium avium complex (MAC) in respiratory specimens
by using the AMPLICOR test. The direct tests, however, have some
drawbacks (2, 3, 7), such as a low sensitivity for
AFB-smear-negative samples, and thus conventional smear and culture
techniques are still needed.
We present here a case of a patient with pulmonary tuberculosis who was
coinfected with MAC and whose sputum contained both of the
mycobacteria. We detected M. tuberculosis alone in the sputum by the AMPLICOR test. The unrecognized coexistence of MAC seriously modified the results of subsequent drug susceptibility tests.
We also performed experiments to investigate the effect of the
coexistence of MAC with M. tuberculosis on the results of
AMPLICOR, AccuProbe, and drug susceptibility tests.
Case report.
A 64-year-old man was admitted to our hospital in
April 1996 because of persistent cough. A chest roentgenogram revealed
diffuse cavitary infiltrates in both lung fields. The Mantoux test with purified protein derivative (2.5 tuberculin units) was strongly positive (dimensions of redness, 32 by 20 mm). Because microscopic examination of the sputum sample revealed numerous AFB, we performed the AMPLICOR test, which showed that the sample contained M. tuberculosis without MAC (optical density at 450 nm [OD] = 1.954 for M. tuberculosis, OD = 0.044 for M. avium, and OD = 0.037 for Mycobacterium
intracellulare). Isoniazid (INH), rifampin (RFP), and ethambutol
(EB) were administered based on the diagnosis of pulmonary
tuberculosis. The sample was cultured both on a slant of Ogawa egg
medium and in the Mycobacterium Growth Indicator Tube (MGIT; Becton
Dickinson, Sparks, Md.) system (4, 10, 12, 14, 16). After 10 days, a positive fluorescent signal was detected in the MGIT system.
The growing bacterium was identified as M. tuberculosis by
the acid fastness and probe analysis determined by using the AccuProbe
test. Based on drug susceptibility test results of the MGIT system, the
recovered mycobacteria were determined to be resistant to all drugs
tested (INH, RFP, EB, and streptomycin [SM]). Thus, a new regimen was started. After 4 weeks of culture, heavy growth of homogeneous rough
colonies had developed on the Ogawa slant; these colonies were again
identified as M. tuberculosis by using the AccuProbe test.
The drug susceptibility testing for the mycobacteria grown on the slant
with 1% Ogawa egg medium (8) also revealed resistance to
all drugs tested. However, the fact that colonies had also grown on
medium containing 500 µg of p-nitrobenzoic acid (PNB) per
ml, which inhibits the growth of M. tuberculosis (5,
13), led us to suspect that some colonies of nontuberculous
mycobacteria had been recovered from the sputum sample collected at the
time of patient admission. Thus, we identified all colonies recovered from the patient's sputum samples that had been stored in our laboratory by using probes for both M. tuberculosis and MAC.
As shown in Table 1, the recovered
mycobacteria consisted of M. tuberculosis alone, MAC alone,
and both mycobacteria, on different occasions. Testing for colonies
containing M. tuberculosis alone by using the MGIT system
and the Ogawa method revealed susceptibility to INH, RFP, and SM. The
patient was put on a new regimen containing those drugs starting in
July. The patient's sputum was found to be both smear and culture
negative in September.
Experiment 1. Separation of M. tuberculosis colonies
from MAC colonies in the mycobacteria recovered from the sputum sample
collected upon patient admission.
To confirm the mixed recovery of
M. tuberculosis and MAC, we tried to separate the two
mycobacterial colonies from each other. Colonies were lifted from the
Ogawa slant and cultured in modified Dubos Tween albumin liquid medium
(11) for 14 days. The bacterial suspensions were diluted a
millionfold, and the dilutions were plated on a Middlebrook 7H10 agar
plate (Difco, Detroit, Mich.). Various types of colonies were grown on
the agar, six of which were selected and cultured in Dubos medium
again. After 14 days, the bacteria in each suspension were identified
by using the AccuProbe test and drug susceptibility testing was done
with the MGIT system. Two M. tuberculosis strains obtained
were resistant to EB alone. Two MAC strains were resistant to INH, RFP,
and EB, while the other MAC strain was resistant to INH, RFP, EB, and
SM. One mixed strain was resistant to INH, RFP, and EB. These results
indicated that the recovery of a mixture of MAC and M. tuberculosis from the sputum sample collected upon admission
modified the results of the drug susceptibility testing.
Experiment 2. Rapid identification of the samples containing both
M. tuberculosis and M. avium by the AMPLICOR
test.
The case described herein encouraged us to investigate the
effect of the coexistence of MAC with M. tuberculosis on the
results of the AMPLICOR test. Various numbers of CFU of M. tuberculosis H37Rv and M. avium Mino (15)
were added to sample tubes containing 5 ml of saline, and each sample
was analyzed by the AMPLICOR test. As shown in Table
2, both mycobacteria were detected only
when the numbers of CFU of M. avium were the same, 10 or 100 times higher than those of M. tuberculosis (samples B to D).
The same samples were cultured, and the drug susceptibilities of the
grown bacteria were tested by using the MGIT system. Samples A to E showed resistance to all drugs tested, and sample F showed resistance to INH, EB, and SM. The grown bacteria were identified by the AccuProbe
test as well. Samples A to F were identified as both M. tuberculosis and MAC, while samples G and H were identified as M. tuberculosis alone. These results demonstrated that
coexistence of certain numbers of MAC with M. tuberculosis
(samples E and F) could not be detected by the AMPLICOR test but could
have a serious effect on the subsequent drug susceptibility testing.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Results of AMPLICOR, MGIT, and AccuProbe tests for
samples containing known CFU of both M. tuberculosis and
M. aviuma
|
|
A patient with pulmonary tuberculosis is sometimes transiently
coinfected with nontuberculous mycobacteria, but antituberculosis chemotherapy alone is sufficient to eradicate both of the mycobacteria, as described previously (6). This coinfection can usually be recognized by the presence of different types of colony formation on
the solid medium, agar-based culture plate in particular, in which case
each colony can be separately identified. In the case reported herein,
however, homogeneous rough colonies on the Ogawa slant prevented the
recognition of the coexistence. Moreover, the result of the AMPLICOR
test led us to neglect to rule out the coexistence of MAC in the grown
bacteria by using the AccuProbe test. Finally, colonies grown on the
Ogawa medium with PNB demonstrated to us the coexistence of
nontuberculous mycobacteria (5, 13). The present
experimental data also documented the limitations of the AMPLICOR test
to rule out the coexistence of MAC with M. tuberculosis in a
sample. Clinical specimens must be cultured not only in a broth but
also on both egg-based and agar-based media for visual inspection. In
addition, medium with PNB or
p-nitro-
-acetylamino-
-hydroxy-propiophenone (NAP)
should be used to rule out the coexistence of nontuberculous mycobacteria. Moreover, if unusual susceptibility test results occur,
an intensive search for a second species should be performed as well.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Infection and Inflammation, Chest Disease Research Institute, Kyoto
University, Sakyo-ku, Kyoto, 606 Japan. Phone: 81-75-751-3828. Fax:
81-75-752-9017. E-mail:ksuzuki{at}chest.kyoto-u.ac.jp.
 |
REFERENCES |
| 1.
|
Abe, C.,
K. Hirano,
M. Wada,
Y. Kazumi,
M. Takahashi,
Y. Fukasawa,
T. Yoshimura,
C. Miyagi, and S. Goto.
1993.
Detection of Mycobacterium tuberculosis in clinical specimens by polymerase chain reaction and Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test.
J. Clin. Microbiol.
31:3270-3274[Abstract/Free Full Text].
|
| 2.
|
Abe, C.,
T. Mori,
E. Fujii,
M. Asaba,
H. Utagawa,
K. Okazawa,
S. Hiyoshi,
K. Hoshino,
Y. Ashihara,
Y. Sakai, and T. Narisawa.
1995.
Reproducibility of MTD system for detection of Mycobacterium tuberculosis: a cooperative study among six laboratories.
Kekkaku
70:467-472[Medline]. (Abstract in English.)
|
| 3.
|
American Thoracic Society Workshop.
1997.
Rapid diagnostic tests for tuberculosis.
Am. J. Respir. Crit. Care Med.
155:1804-1814[Abstract].
|
| 4.
|
Badak, F. Z.,
D. L. Kiska,
S. Setterquist,
C. Hartley,
M. A. O'Connell, and R. L. Hopfer.
1996.
Comparison of Mycobacteria Growth Indicator Tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens.
J. Clin. Microbiol.
34:2236-2239[Abstract].
|
| 5.
|
Collins, T., and P. N. Levett.
1989.
Radiometric studies on the use of selective inhibitors in the identification of Mycobacterium spp.
J. Med. Microbiol.
30:175-181[Abstract].
|
| 6.
|
Epstein, M. D.,
C. P. Arannda,
S. Bonk, and W. N. Rom.
1997.
The significance of Mycobacterium avium complex cultivation in the sputum of patients with pulmonary tuberculosis.
Chest
111:142-147[Abstract/Free Full Text].
|
| 7.
|
Grosset, J., and Y. Mouton.
1995.
Is PCR a useful tool for the diagnosis of tuberculosis in 1995?
Tubercle Lung Dis.
76:183-184[Medline].
|
| 8.
|
Hirano, K.,
C. Kazumi,
T. Abe,
T. Mori,
M. Aoki, and T. Aoyagi.
1996.
Resistance to antituberculosis drugs in Japan.
Tubercle Lung Dis.
77:130-135[Medline].
|
| 9.
|
Ichiyama, S.,
Y. Iinuma,
Y. Tawada,
S. Yamori,
Y. Hasegawa,
K. Shimokata, and N. Nakashima.
1996.
Evaluation of Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test and Roche PCR-microwell plate hybridization method (AMPLICOR MYCOBACTERIUM) for direct detection of mycobacteria.
J. Clin. Microbiol.
34:130-133[Abstract].
|
| 10.
|
Ichiyama, S.,
Y. Iinuma,
S. Yamori,
Y. Hasegawa,
K. Shimokata, and N. Nakashima.
1997.
Mycobacterium Growth Indicator Tube testing in conjunction with the AccuProbe or the AMPLICOR-PCR assay for detecting and identifying mycobacteria from sputum samples.
J. Clin. Microbiol.
35:2022-2025[Abstract].
|
| 11.
|
Kuze, F.,
T. Kurasawa,
K. Bando,
Y. Lee, and N. Maekawa.
1981.
In vitro and in vivo susceptibility of atypical mycobacteria to various drugs.
Rev. Infect. Dis.
3:885-897[Medline].
|
| 12.
|
Palaci, M.,
S. Y. M. Ueki,
D. N. Sato,
M. A. S. Telles,
M. Curcio, and E. A. M. Silva.
1996.
Evaluation of Mycobacteria Growth Indicator Tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens.
J. Clin. Microbiol.
34:762-764[Abstract].
|
| 13.
|
Rastogi, N.,
K. S. Goh, and H. L. David.
1989.
Selective inhibition of the Mycobacterium tuberculosis complex by p-nitro-alpha-acetylamino-beta-hydroxypropio phenone (NAP) and p-nitrobenzoic acid (PNB) used in 7H11 agar medium.
Res. Microbiol.
140:419-423[Medline].
|
| 14.
|
Suzuki, K.,
K. Tsuyuguchi,
H. Matsumoto,
A. Niimi,
E. Tanaka,
T. Murayama,
R. Amitani, and F. Kuze.
1997.
Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis isolates.
Kekkaku
72:187-192[Medline]. (Abstract in English.)
|
| 15.
|
Suzuki, K.,
K. Tsuyuguchi,
H. Matsumoto,
T. Yamamoto,
T. Hashimoto,
E. Tanaka,
R. Amitani, and F. Kuze.
1997.
Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
Int. J. Tuberc. Lung Dis.
1:460-467[Medline].
|
| 16.
|
Walters, S. B., and B. A. Hanna.
1996.
Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by Mycobacterium Growth Indicator Tube method.
J. Clin. Microbiol.
34:1565-1567[Abstract].
|
Journal of Clinical Microbiology, September 1998, p. 2745-2747, Vol. 36, No. 9
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.